Trial of risperidone in India - Concerns [4]

British Journal of Psychiatry

Volumn 188, Issue MAY, 2006, Pages 489-490

  Basil, B ^a   Adetunji, B ^b   Mathews, M ^a   Budur, K ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b MHM Correctional Services   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; RISPERIDONE; NEUROLEPTIC AGENT; PLACEBO;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INFORMED CONSENT; LETTER; MANIA; MEDICAL RESEARCH; MORBIDITY; BIPOLAR DISORDER; CONTROLLED CLINICAL TRIAL; HEALTH PERSONNEL ATTITUDE; INDIA; MEDICAL ETHICS; METHODOLOGY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; STANDARD; ETHICS; LEGAL ASPECT; PSYCHOLOGICAL ASPECT; TREATMENT WITHDRAWAL;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; BIPOLAR DISORDER; ETHICS, CLINICAL; HUMANS; INDIA; JOURNALISM, MEDICAL; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; HELSINKI DECLARATION; INFORMED CONSENT; WITHHOLDING TREATMENT;

EID: 33646517485     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.188.5.489-b     Document Type: Letter

References (3)

1. Post, R. M. (2000) Mood disorders: treatment of bipolar disorders. In Comprehensive Textbook of Psychiatry (eds B. J. Sadock & V. A. Sadock), pp. 1385 1430. Philadelphia, PA: Lippincott Williams & Wilkins.
2. Khanna, S., Vieta, E., Lyons, B., et al (2005) Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. British Journal of Psychiatry, 187, 229-234.
3. World Medical Association (1989) World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. http://www.fda.gov/oc/health/helsinki89.html